Historical salary details - Mr. William F. Doyle, Independent Director, Elanco Animal Health Inc
Mr. William F. Doyle is the Independent Director of Elanco Animal Health Inc.
Mr. William F. Doyle
Independent Director
-
Gross Remuneration
-
Current Company
Elanco Animal Health Inc
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2025 | Elanco Animal Health Inc | Independent Director | - | - |
| 2024 | ProKidney Corp - Ordinary Shares - Class A | Independent Director | 243.1 K | -41.1 % |
| 2024 | NovoCure Ltd | Executive Chairman of the Board | - | - |
| 2024 | Elanco Animal Health Inc | Independent Director | - | - |
| 2023 | NovoCure Ltd | Executive Chairman of the Board | 1.4 M | -33.6 % |
| 2023 | ProKidney Corp - Ordinary Shares - Class A | Independent Director | 413.1 K | -95.7 % |
| 2023 | Elanco Animal Health Inc | Independent Director | 330.0 K | -0.0 % |
| 2023 | Minerva Neurosciences Inc | Lead Independent Director | 32.3 K | -53.9 % |
| 2022 | ProKidney Corp - Ordinary Shares - Class A | Independent Director | 9.7 M | - |
| 2022 | NovoCure Ltd | Executive Chairman of the Board | 2.2 M | 175.8 % |
| 2022 | Elanco Animal Health Inc | Independent Director | 330.0 K | 16.5 % |
| 2022 | Minerva Neurosciences Inc | Lead Independent Director | 70.0 K | -49.2 % |
| 2021 | NovoCure Ltd | Executive Chairman of the Board | 780 K | - |
| 2021 | Elanco Animal Health Inc | Independent Director | 283.3 K | - |
| 2021 | Minerva Neurosciences Inc | Lead Independent Director | 137.7 K | -4.4 % |
| 2021 | ProKidney Corp - Ordinary Shares - Class A | Director | - | - |
| 2020 | Minerva Neurosciences Inc | Lead Independent Director | 144.1 K | -24.1 % |
| 2020 | OptiNose Inc | - | 91.8 K | -8.5 % |
| 2020 | Elanco Animal Health Inc | Independent Director | - | - |
| 2020 | OptiNose Inc | Independent Director | - | - |
| 2020 | NovoCure Ltd | Executive Chairman of the Board | - | - |
| 2019 | Minerva Neurosciences Inc | Lead Independent Director | 189.8 K | -30.4 % |
| 2019 | OptiNose Inc | Independent Director | 100.3 K | -60.2 % |
| 2019 | NovoCure Ltd | Executive Chairman of the Board | - | - |
| 2018 | Minerva Neurosciences Inc | Lead Independent Director | 272.5 K | 67.4 % |
| 2018 | OptiNose Inc | Independent Director | 252.0 K | 2589.5 % |
| 2018 | NovoCure Ltd | Executive Chairman of the Board | - | - |
| 2017 | Minerva Neurosciences Inc | Lead Independent Director | 162.8 K | - |
| 2017 | OptiNose Inc | Independent Director | 9.4 K | - |
| 2017 | NovoCure Ltd | Executive Chairman of the Board | - | - |
| 2016 | NovoCure Ltd | Executive Chairman of the Board | 597.0 K | 99.0 % |
| 2016 | OptiNose Inc | Independent Director | - | - |
| 2016 | Zoetis Inc - Ordinary Shares - Class A | Independent Director | - | - |
| 2015 | NovoCure Ltd | Chairman of the Board | 300 K | 0.0 % |
| 2015 | Zoetis Inc - Ordinary Shares - Class A | Independent Director | - | - |
| 2014 | NovoCure Ltd | Chairman of the Board | 300 K | - |
| 2014 | Zoetis Inc - Ordinary Shares - Class A | Independent Director | - | - |